Benzinga · Feb 10, 2026
Hainan Helpson Medical & Biotechnology Strikes Deal With Xiaoyun Chen To Acquire Invention Patent Of An Topiroxostat Nanoemulsion And Method for Its Preparation For $8.82M
SEC.
AMEX · CPHI
Healthcare · Drug Manufacturers - Specialty & Generic
$0.71
Up+$0.03 (+3.68%)
Updated Sep 18, 2026, 3:37 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CPHI closed at $0.71 after 20 trading sessions, down 32.92% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $0.72 | $0.7336 | $0.71 | $0.711 | 73.64K |
| Sep 16, 2026 | $0.72 | $0.7417 | $0.70 | $0.7266 | 91.88K |
| Sep 15, 2026 | $0.75 | $0.7587 | $0.7207 | $0.7307 | 84.42K |
| Sep 14, 2026 | $0.78 | $0.7836 | $0.7647 | $0.7785 | 69.68K |
| Sep 11, 2026 | $0.77 | $0.78 | $0.76 | $0.7603 | 64.31K |
| Sep 10, 2026 | $0.82 | $0.82 | $0.7577 | $0.763 | 103.4K |
| Sep 9, 2026 | $0.82 | $0.8523 | $0.7745 | $0.779 | 84.76K |
| Sep 8, 2026 | $0.8353 | $0.854 | $0.8204 | $0.841 | 118.19K |
| Sep 4, 2026 | $0.8401 | $0.8451 | $0.82 | $0.8201 | 77.31K |
| Sep 3, 2026 | $0.84 | $0.8628 | $0.84 | $0.84 | 57.92K |
| Sep 2, 2026 | $0.8587 | $0.8599 | $0.83 | $0.845 | 112.68K |
| Sep 1, 2026 | $0.88 | $0.90 | $0.8752 | $0.8853 | 181.49K |
| Aug 31, 2026 | $0.9246 | $0.9575 | $0.866 | $0.8855 | 406.08K |
| Aug 28, 2026 | $0.915 | $0.92 | $0.886 | $0.9041 | 124.74K |
| Aug 27, 2026 | $0.9059 | $0.9552 | $0.8861 | $0.8861 | 146.51K |
| Aug 26, 2026 | $0.88 | $0.999 | $0.88 | $0.8991 | 520.87K |
| Aug 25, 2026 | $0.9574 | $0.96 | $0.861 | $0.874 | 241.25K |
| Aug 24, 2026 | $1.00 | $1.00 | $0.915 | $0.95 | 222.87K |
| Aug 21, 2026 | $1.031 | $1.05 | $0.9625 | $0.98 | 309.12K |
| Aug 20, 2026 | $1.05 | $1.07 | $1.01 | $1.06 | 223.48K |
The latest Smart Investors Daily articles mentioning CPHI.
CPHI research
Company profile and research snapshot.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Feb 10, 2026
SEC.
defenseworld.net · Dec 12, 2025
Shares of China Pharma Holdings, Inc. (NYSE: CPHI - Get Free Report) were down 10.2% during mid-day trading on Thursday. The stock traded as low as $1.48 and last traded at $1.50. Approximately 42,122 shares changed hands during mid-day trading, a decline of 48% from the average daily volume of 81,489 shares. The stock had
prnewswire.com · Nov 4, 2025
/PRNewswire/ -- The Taiwan Traditional Chinese Medicine (TCM) Pavilion, guided by the Department of Chinese Medicine and Pharmacy (DCMP) under the Ministry of
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning CPHI.